This inventor holds 1 USPTO granted patent and 7 published patent applications. Top assignee: Pure Tech Lyt 100, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Varun Garg and His Work on Deupirfenidone
Introduction
Varun Garg is an inventor associated with Framingham, Massachusetts. His patent work concerns a proposed treatment for idiopathic pulmonary fibrosis (IPF) using deupirfenidone, also known as LYT-100. The available information identifies him as a man and lists PureTech LYT-100, Inc. as his company.
Latest Patents
Garg is named on one patent, “Methods of Treating Idiopathic Pulmonary Fibrosis with Deupirfenidone.” The disclosed method involves administering deuterium-enriched pirfenidone, LYT-100, to a person with IPF at a total daily dose of about 1,650 mg to about 2,500 mg. The patent describes the method and dose range; it does not, by itself, establish clinical effectiveness or regulatory approval.
Career Highlights
The information provided connects Garg’s work to the development of LYT-100 and research into potential treatments for IPF. His listed patent focuses on a specific therapeutic compound and dosing approach.
Collaborations
Garg’s listed coworkers include Michael C. Chen and Eric Elenko. The available details do not specify their roles in the patent or the broader research program.
Conclusion
Varun Garg’s identified patent work centers on a proposed LYT-100 treatment method for idiopathic pulmonary fibrosis, reflecting a focused contribution to pharmaceutical innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile